T. Rowe Price Associates
CGEM icon

T. Rowe Price Associates’s Cullinan Oncology CGEM Stock Holding History

T. Rowe Price Associates’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.7M Buy
3,825,950
+1,796,231
+88% +$26.7M 0.01% 792
2026
Q1 		$28.8M Buy
2,029,719
+1,982,532
+4,201% +$25.5M ﹤0.01% 940
2025
Q4 		$489K Buy
47,187
+3,950
+9% +$35.6K ﹤0.01% 2410
2025
Q3 		$257K Buy
43,237
+6,820
+19% +$49.9K ﹤0.01% 2681
2025
Q2 		$275K Buy
36,417
+4,696
+15% +$37.7K ﹤0.01% 2567
2025
Q1 		$241K Buy
31,721
+2,228
+8% +$21.4K ﹤0.01% 2557
2024
Q4 		$360K Buy
29,493
+3,924
+15% +$56.4K ﹤0.01% 2428
2024
Q3 		$429K Buy
25,569
+4,770
+23% +$84.6K ﹤0.01% 2322
2024
Q2 		$363K Sell
20,799
-2,043
-9% -$43.5K ﹤0.01% 2325
2024
Q1 		$390K Buy
22,842
+820
+4% +$12.7K ﹤0.01% 2309
2023
Q4 		$225K Buy
22,022
+7,620
+53% +$67.5K ﹤0.01% 2492
2023
Q3 		$131K Hold
14,402
– – ﹤0.01% 2608
2023
Q2 		$155K Buy
14,402
+365
+3% +$3.88K ﹤0.01% 2597
2023
Q1 		$144K Sell
14,037
-15
-0.1% -$165 ﹤0.01% 2608
2022
Q4 		$148K Buy
14,052
+435
+3% +$5.28K ﹤0.01% 2622
2022
Q3 		$175K Buy
13,617
+1,871
+16% +$25.2K ﹤0.01% 2589
2022
Q2 		$151K Buy
11,746
+619
+6% +$7.02K ﹤0.01% 2662
2022
Q1 		$116K Buy
11,127
+500
+5% +$6.75K ﹤0.01% 2824
2021
Q4 		$164K Buy
+10,627
New +$212K ﹤0.01% 2801
2021
Q2 		– Sell
-723,584
Closed -$30.2M – 2925
2021
Q1 		$30.2M Buy
+723,584
New +$29.4M ﹤0.01% 1170

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates's CGEM Position: Q2 2026 in Review

T. Rowe Price Associates increased its Cullinan Oncology (CGEM) stake by 88% in Q2 2026, buying an estimated $26.7M and bringing the position to 3,825,950 shares worth $69.7M. The position accounts for 0.01% of the portfolio, ranked #792.

T. Rowe Price Associates first reported a position in CGEM in Q1 2021 and has held it in 20 quarters since. 183 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • T. Rowe Price Associates held 3,825,950 shares of Cullinan Oncology worth $69.7M as of Q2 2026.
  • T. Rowe Price Associates bought 1,796,231 Cullinan Oncology shares in Q2 2026, an estimated $26.7M.
  • Cullinan Oncology made up 0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #792 holding.
  • T. Rowe Price Associates first reported a position in Cullinan Oncology in Q1 2021 and has held it in 20 quarters since.
  • 183 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.